Clinical Trials Logo

Chromosome Deletion clinical trials

View clinical trials related to Chromosome Deletion.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT05187377 Enrolling by invitation - Clinical trials for Autism Spectrum Disorder (ASD)

A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism

Start date: January 19, 2022
Phase: Phase 2
Study type: Interventional

This clinical trial will use growth hormone as a novel treatment for Phelan-McDermid syndrome (PMS) and idiopathic autism. A double-blind, placebo-controlled crossover trial design will be used in 30 children with idiopathic autism and 15 children with PMS to evaluate the the effects of growth hormone on visual evoked potentials (VEPs), socialization, language, and repetitive behaviors. The researchers expect to provide evidence for the feasibility of using VEPs in PMS, and to show support for growth hormone in ameliorating clinical symptoms of ASD.

NCT ID: NCT04312152 Enrolling by invitation - Clinical trials for Autism Spectrum Disorder

Q10 Ubiquinol in Autism Spectrum Disorder and in Phelan-McDermid Syndrome.

Q10ASD
Start date: March 9, 2019
Phase: N/A
Study type: Interventional

This double-blind, cross-over, randomized, controlled trial (RCT) has the aim of evaluating the effectiveness of a metabolic support therapy in two cohorts of patients with idiopathic Autism Spectrum Disorder or Phelan-McDermid syndrome, commonly associated with syndromic autism. Each patient will receive Q10 ubiquinol + Vit. E and B for 4 months and only Vit. E and B for 4 months in a double-blind, cross-over design. Primary outcome measures of efficacy include Vineland Adaptive Behavior Scales, Childhood Autism Rating Scale, Clinical Global Impression-Improvement and Visual Analog Scales; secondary outcome measures include several questionnaires and tests of autism, cognitive function, problem behaviors, quality of life, communication and comorbid disorders, as well as measures of oxidative stress.

NCT ID: NCT02640443 Enrolling by invitation - Clinical trials for Isolated PREPL Deficiency

Sulfamethoxazole for the Treatment of Primary PREPL Deficiency

SPPD
Start date: October 2015
Phase: Phase 2
Study type: Interventional

The investigators will evaluate whether sulfamethoxazole, a sulfamide antibiotic, improves the symptoms of primary PREPL deficiency (hypotonia-cystinuria syndrome and isolated PREPL deficiency).